Chemomab Therapeutics Q3 2026 net loss triples year over year to $5.1 million
CMMB•Chemomab Therapeutics reported a third-quarter 2026 net loss of $5.1 million, triple the year-earlier amount, while cash and short-term bank deposits fell 30% from June 30 to $4.7 million. Its proposed merger with Scipher Medicine is expected to close in Q1 2027, subject to shareholder approval and closing conditions.
1. Quarterly results
Chemomab Therapeutics’ third-quarter 2026 net loss tripled year over year to $5.1 million. Research and development expenses more than tripled to $3.7 million, primarily due to recognition of prepaid manufacturing costs. Cash, cash equivalents and short-term bank deposits were $4.7 million at September 30, down 30% from June 30.
2. Merger and trial plans
The proposed merger with Scipher Medicine is expected to close in the first quarter of 2027, subject to shareholder approval and closing conditions. After closing, the combined company plans to initiate a Phase 2 nebokitug rheumatoid arthritis trial in the first half of 2027.




